ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Cancer Ther
Main Authors: Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C., Tiv, Hong L., Knott, Aine R., Wilkens, Margaret K., Soroko, Kara M., Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A., Chambers, Emily S., Paweletz, Cloud P., Bhagwat, Shripad V., Manro, Jason R., Tiu, Ramon V., Jänne, Pasi A.
Format: Artigo
Jezik:Inglês
Izdano: 2021
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026682/
https://ncbi.nlm.nih.gov/pubmed/33536188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0531
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki